761440-68-0

Basic information

• Product Name: Piperidine, 4-(3-methoxy-4-nitrophenoxy)-1-methyl-
• CAS NO: 761440-68-0
• Molecular Formula: C13H18N2O4
• Molecular Weight: 266.297
• Mol File: 761440-68-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Piperidine, 4-(3-methoxy-4-nitrophenoxy)-1-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperidine, 4-(3-methoxy-4-nitrophenoxy)-1-methyl-(761440-68-0)
• EPA Substance Registry System: Piperidine, 4-(3-methoxy-4-nitrophenoxy)-1-methyl-(761440-68-0)

Safety Data

• Hazardous Substances Data: 761440-68-0(Hazardous Substances Data)

Upstream product

• 106-52-5 N-methyl-4-hydroxypiperidine 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 

Downstream Products

• 761440-71-5 2-methoxy-4-(1-methylpiperidin-4-yloxy)aniline 

Relevant articles and documents

PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY

The present invention provides a method for identifying a tumor - in a human individual or in an animal - that is susceptible to treatment with a TTK inhibitor, said method comprising: a] providing a sample of a tumor; b] determining the presence of a mutated CTNNB1 gene in said tumor sample, wherein said mutation is located in exon 3 of CTNNB1 and whereby the presence of a mutated CTNNB1 gene indicates that the tumor is susceptible to treatment with a TTK inhibitor. In an alternative aspect, step b] of the above defined method is replaced by the step of determining the presence of a mutated CTNNB1 protein in said tumor sample, wherein said mutation is located in exon 3 of CTNNB1 and whereby the presence of a mutated CTNNB1 protein indicates that the tumor is susceptible to treatment with a TTK inhibitor. In a further alternative, step b] comprises determining an altered expression of a CTNNB1 regulated gene, whereby an altered expression of a CTNNB1 regulated gene indicates that the tumor is susceptible to treatment with a TTK inhibitor.

(5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES

The invention relates to a compound of Formula (I) wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.

2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS

Novel pyrimidine derivatives of formula (I), to processes for their production, their use as pharmaceuticals in the treatment of neoplastic diseases, inflammatory and immune system disorders and to pharmaceutical compositions comprising them.